LA JOLLA, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from the ongoing Phase 2 clinical trial evaluating the efficacy, safety and biomarkers of tipifarnib in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) were selected for a poster presentation at the 14th International Conference on Malignant Lymphoma (ICML) being held June 14-17, 2017 in Lugano, Switzerland. In addition, Kura’s preliminary Phase 2 data in PTCL were also selected for a poster presentation at the 22nd Congress of the European Hematology Association (EHA) taking place June 22-25, 2017 in Madrid, Spain.
Details for the Poster Presentation at ICML
Title: Preliminary Results from an Open-label, Phase II Study of Tipifarnib in Relapsed or Refractory T-cell Lymphoma
Presenter: Thomas E. Witzig, M.D., Mayo Clinic
Abstract Number: 255
Date and Time: Wednesday, June 14, 2017, poster may be viewed from Wednesday, June 14, 2017 at 12:00 CET through Friday, June 16, 2017 at 18:30 CET
Location: Marquee Parco Ciani
Details for the Poster Presentations at EHA
Title: Preliminary Results from an Open-label, Phase II Study of Tipifarnib in Relapsed or Refractory T-cell Lymphoma
Presenter: Thomas E. Witzig, M.D., Mayo Clinic
Abstract Number: P571
Poster Session: EHA 22
Date / Time: Saturday, June 24, 2017, 7:30 – 19:00 CET
Location: IFEMA, Poster Area, Hall 7
In addition, data from a preclinical study of tipfarnib in T-cell leukemia by Dr. Mondejar (IDIVAL, Santander, Spain) showing cell line sensitivity to common T leukemia mutations will be presented at EHA as an E-poster.
Title: T-Cell Leukemia Sensitivity to Farnesyl Transferase Inhibition Using Tipifarnib
Abstract Number: E834
Date / Time: Friday, June 23, 09:30 CET through Saturday, June 24, 19:30 CET
Location: Poster Area, E-poster screens
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology, Inc.
